5

15

20

25

30

35



What Is Claimed Is:

- 1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) residues 27 to 336 of SEQ ID NO:2;
 - (b) residues 1 to 441 of SEQ ID NO:4;
 - (c) residues 25 to 574 of SEQ ID NO:6; and
 - (d) residues 1 to 388 of SEQ ID NO:8.
- The isolated nucleic acid molecule of claim comprising the nucleotide sequence shown as nucleotides 1-1008 of SEQ ID NO:1.
 - 3. The isolated nucleic acid molecule of claim 1 comprising the nucleotide sequence shown as nucleotides 2-1324 of SEQ ID NO:3.
 - 4. The isolated nucleic acid molecule of claim L comprising the nucleotide sequence shown as nucleotides 130-1751 of SEQ ID No. 5.
 - 5. The isolated nucleic acid molecule of claim 1 comprising the nucleotide sequence shown as nucleotides 3-1166.
 - 6. An isolated nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence selected from the group consisting of:
 - (a) at least 30 contiguous amino acid residues of SEQ ID NO:2;
 - (b) at least 30 contiguous amino acid residues of SEQ ID NO:4;
 - (c) at least 30 configuous amino acid residues of SEQ ID NO:6; and
 - (d) at least 30 contiguous amino acid residues of SEQ ID NO:8.
 - 7. A vector comprising the isolated nucleic acid molecule of claim 1.
 - 8. A pucleic acid molecule comprising the nucleic acid molecule of claim 1 operably associated with a heterologous regulatory element which controls gene expression.
 - 9. A host cell comprising the vector or claim 7.
 - 10 A host cell comprising the nucleic acid molecule of claim 8.
 - 1. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

- (a) residues 27 to 336 of SEQ ID NO:2;(b) residues 1 to 441 of SEQ ID NO:4;
- (c) residues 25 to 574 of SEQ ID NO:6; and
- (d) residues 1 to 388 of SEQ ID NO:8.

5

10

15

20

- 12. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) at least 30 contiguous amino acid residues of SEQ ID NO:2;
 - (b) at least 30 contiguous amino acid residues of SEQ ID/NO:4;
 - (c) at least 30 contiguous amino acid residues of SEQ ID NO:6; and
 - (d) at least 30 contiguous amino acid residues of SEQID NO:8.
 - 13. An isolated antibody that binds specifically/to the isolated polypeptide of claim

11.

14. A composition comprising the polypoptide of claim 11.

- 15. A method of making an isolated polypeptide comprising:
- (a) culturing the host cell of claim 10 under conditions such that said polypeptide is expressed; and
 - (b) recovering said polypeptide.
 - 16. The polypeptide produced by the method of claim 15.
- 25 17. A method for treating a medical condition, comprising administering to a patient a therapeutically effective amount of the polypeptide of claim 11.
 - 18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- 30 (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence of absence of said mutation.
- 35 19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
 - (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample, and

- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
- 20. A method for identifying a binding partner to the polypeptide of claim 11 5 comprising:
 - (a) contacting the polypeptide of claim 11 with a binding partner; and
 - (b) determining whether the binding partner effects an activity of the polypeptide.